CELU vs. XBI
CELU (Celularity Inc.) is a stock, while XBI (SPDR S&P Biotech ETF) is Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index. Over the past 5 years, CELU returned -63.06%/yr vs 1.51%/yr for XBI. At a 0.18 correlation, their price movements are largely independent.
Performance
CELU vs. XBI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CELU achieves a -36.95% return, which is significantly lower than XBI's 20.70% return.
CELU
- 1D
- -7.68%
- 1M
- -19.57%
- YTD
- -36.95%
- 6M
- -45.75%
- 1Y
- -65.18%
- 3Y*
- -52.91%
- 5Y*
- -63.06%
- 10Y*
- —
XBI
- 1D
- 0.80%
- 1M
- 11.78%
- YTD
- 20.70%
- 6M
- 17.84%
- 1Y
- 79.53%
- 3Y*
- 20.24%
- 5Y*
- 1.51%
- 10Y*
- 11.14%
CELU vs. XBI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
CELU Celularity Inc. | -36.95% | -46.63% | -15.93% | -80.82% | -74.80% | -53.45% | 10.55% | 1.53% |
XBI SPDR S&P Biotech ETF | 20.70% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 14.14% |
Correlation
The correlation between CELU and XBI is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Aug 8, 2019 | 0.18 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CELU vs. XBI — Risk / Return Rank
CELU
XBI
CELU vs. XBI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Celularity Inc. (CELU) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CELU | XBI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.67 | ||
| Sortino ratioReturn per unit of downside risk | -4.68 | ||
| Omega ratioGain probability vs. loss probability | 0.90 | 1.47 | -0.56 |
| Calmar ratioReturn relative to maximum drawdown | -0.78 | 8.22 | -9.01 |
| Martin ratioReturn relative to average drawdown | -1.10 | 24.30 | -25.40 |
Loading charts...
Drawdowns
CELU vs. XBI - Drawdown Comparison
The maximum CELU drawdown since its inception was -99.47%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for CELU and XBI.
Loading charts...
Drawdown Indicators
| CELU | XBI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.47% | -63.89% | -35.58% |
Max Drawdown (1Y)Largest decline over 1 year | -83.41% | -9.72% | -73.69% |
Max Drawdown (3Y)Largest decline over 3 years | -90.11% | -32.99% | -57.12% |
Max Drawdown (5Y)Largest decline over 5 years | -99.47% | -54.71% | -44.76% |
Max Drawdown (10Y)Largest decline over 10 years | — | -63.89% | — |
Current DrawdownCurrent decline from peak | -99.46% | -14.94% | -84.52% |
Average DrawdownAverage peak-to-trough decline | -63.16% | -20.93% | -42.23% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 59.30% | 3.28% | +56.02% |
Volatility
CELU vs. XBI - Volatility Comparison
Celularity Inc. (CELU) has a higher volatility of 32.85% compared to SPDR S&P Biotech ETF (XBI) at 9.96%. This indicates that CELU's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CELU | XBI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 32.85% | 9.96% | +22.89% |
Volatility (6M)Calculated over the trailing 6-month period | 57.68% | 21.31% | +36.37% |
Volatility (1Y)Calculated over the trailing 1-year period | 101.89% | 26.47% | +75.42% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 122.40% | 32.30% | +90.10% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 105.04% | 32.01% | +73.03% |
Dividends
CELU vs. XBI - Dividend Comparison
CELU has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.39%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CELU Celularity Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.39% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Frequently Asked Questions
CELU and XBI have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CELU has higher volatility (32.85%) compared to XBI (9.96%). In terms of maximum drawdown, CELU dropped -99.47% vs XBI's -63.89%.
XBI currently has the higher Sharpe Ratio (3.02 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CELU and XBI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer